Immuron granted patent for anti-influenza product
Wednesday, 02 March, 2011
Melbourne-based Immuron scored a win today with the granting of an Australian patent for its influenza prevention product, Imm-255.
The patent, issued by the Australian Patents Office, provides protection through to 2028.
Imm-255 uses dairy-derived polyclonal influenza-specific antibodies, which are applied to oral and respiratory surfaces.
The antibodies have to date shown positive results in treating and preventing influenza in mice and ferrets, including treating H1N1.
Once animal trials have concluded, Immuron intends to proceed towards clinical trials in humans.
Immuron's (ASX:IMC) stock dropped $0.004 to 7.1c in morning trading.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
